Brokerages Set BioNTech SE (NASDAQ:BNTX) Target Price at $140.76

BioNTech SE (NASDAQ:BNTX) has received an average rating of “Moderate Buy” from the seventeen brokerages that are presently covering the company, MarketBeat Ratings reports. Four analysts have rated the stock with a hold recommendation, twelve have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $140.76.

A number of equities analysts have recently weighed in on the company. BMO Capital Markets reissued an “outperform” rating on shares of BioNTech in a report on Monday, December 2nd. HSBC upped their target price on BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a research report on Monday, October 7th. Jefferies Financial Group upgraded shares of BioNTech from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $96.00 to $150.00 in a report on Tuesday, September 17th. Berenberg Bank started coverage on shares of BioNTech in a research note on Tuesday, November 19th. They set a “buy” rating and a $130.00 price objective on the stock. Finally, TD Cowen decreased their price objective on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a report on Tuesday, November 5th.

BioNTech Stock Down 0.3 %

Shares of BioNTech stock opened at $113.77 on Friday. The company has a market cap of $27.28 billion, a P/E ratio of -54.18 and a beta of 0.22. The firm has a fifty day moving average of $112.97 and a two-hundred day moving average of $101.24. BioNTech has a one year low of $76.53 and a one year high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $514.08 million. During the same period last year, the company posted $0.73 earnings per share. The firm’s quarterly revenue was up 38.9% compared to the same quarter last year. On average, analysts forecast that BioNTech will post -3.72 earnings per share for the current year.

Hedge Funds Weigh In On BioNTech

Several hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC boosted its position in shares of BioNTech by 21.7% in the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock valued at $74,000 after purchasing an additional 111 shares during the period. Blue Trust Inc. increased its stake in shares of BioNTech by 491.1% during the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after purchasing an additional 388 shares during the last quarter. Gallacher Capital Management LLC boosted its stake in shares of BioNTech by 12.1% during the 2nd quarter. Gallacher Capital Management LLC now owns 3,657 shares of the company’s stock worth $294,000 after acquiring an additional 395 shares in the last quarter. TD Asset Management Inc increased its holdings in shares of BioNTech by 6.1% during the 2nd quarter. TD Asset Management Inc now owns 7,590 shares of the company’s stock valued at $612,000 after acquiring an additional 435 shares during the last quarter. Finally, Planning Capital Management Corp lifted its stake in shares of BioNTech by 45,000.0% in the third quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock worth $54,000 after buying an additional 450 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.